Hansa Biopharma Reports Third Quarter and Interim Year to Date 2026 Financial Results

LUND, Sweden, Nov. 11, 2026 // -- Hansa Biopharma AB, "Hansa" (NASDAQ Stockholm: HNSA), today announced its interim report for the three and nine months ended September 30, 2026.Renée Aguiar-Lucander, CEO, Hansa Biopharma, said, "This was a quarter of strong execution for Hansa. The closi…